tiprankstipranks
Trending News
More News >

Acurx assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Acurx (ACXP) with a Buy rating and $8 price target Acurx is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria, the analyst tells investors in a research note. The firm believes the company is “flying under the radar with investors” into a “paradigm shifting moment in anti-infectives.”

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue